Kyowa Kirin
4151.TKyowa Kirin is a leading specialty pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on rare diseases and oncology. The company has built a robust pipeline through internal R&D capabilities and strategic partnerships, with particular expertise in antibody engineering and cell therapy technologies. Kyowa Kirin operates globally with a presence in Japan, Asia-Pacific, North America, and Europe, and is publicly traded on the Tokyo Stock Exchange.
4151.T · Stock Price
Historical price data
AI Company Overview
Kyowa Kirin is a leading specialty pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on rare diseases and oncology. The company has built a robust pipeline through internal R&D capabilities and strategic partnerships, with particular expertise in antibody engineering and cell therapy technologies. Kyowa Kirin operates globally with a presence in Japan, Asia-Pacific, North America, and Europe, and is publicly traded on the Tokyo Stock Exchange.
Technology Platform
Kyowa Kirin leverages proprietary antibody engineering platforms including POTELLIGENT and COMPLEGENT technologies, combined with advanced cell therapy manufacturing and fermentation capabilities for developing innovative biologics and specialty therapeutics.
Pipeline
236| Drug | Indication | Stage | Watch |
|---|---|---|---|
| KRN23 | Tumor-Induced Osteomalacia (TIO) | Approved | |
| Istradefylline Pill | Parkinson Disease | Approved | |
| Mogamulizumab | Cutaneous T-Cell Lymphoma | Approved | |
| KRN23 | X-linked Hypophosphatemia (XLH) | Approved | |
| KHK4827-Active + KHK4827-Placebo | Moderate to Severe Plaque Psoriasis | Approved |
FDA Approved Drugs
4Opportunities
Risk Factors
Competitive Landscape
Kyowa Kirin competes with global rare disease specialists like BioMarin and Alexion, as well as major pharmaceutical companies with oncology franchises. The company differentiates through its proprietary antibody technologies, Asian market presence, and focused rare disease expertise.